|
Company Press
Release
AMERICAN SHARED HOSPITAL SERVICES ORDERS FOUR
LEKSELL GAMMA KNIFE® PERFEXION™ SYSTEMS FOR
CLINICAL PARTNER SITE UPGRADES
San Francisco, CA,
November 6, 2006 -- AMERICAN SHARED HOSPITAL SERVICES (AMEX,PCX:AMS), a
leading provider of turnkey technology solutions for advanced radiosurgical
and radiation therapy services, announced today that it has ordered four
Leksell Gamma Knife® Perfexion™ systems from Elekta AB (Stockholm Stock
Exchange:EKTAb) for planned upgrades of AMS clinical partner sites in the
United States.
"Our decision to purchase
these advanced new systems is the latest example of AMS' commitment to
offering our clinical partners today's most advanced radiosurgery and
radiation therapy technology solutions to improve patient outcomes," said
Ernest A. Bates, M.D., Chairman and Chief Executive Officer of AMS. "Leksell
Gamma Knife Perfexion expands the Gamma Knife product line with a completely
new system that takes stereotactic radiosurgery to the next level, and
provides a platform for further refinement and expansion of radiosurgery
procedures in the brain, skull, cervical spine and head & neck regions."
Dr. Bates said that delivery of these new systems is expected to begin in
the spring of 2007.
Tomas Puusepp, President and
Chief Executive Officer of Elekta, said, "We are pleased to further develop
our collaboration with AMS by delivering these four units to AMS customers,
who will be among the very first in the world to have Leksell Gamma Knife
Perfexion installed. Initial reports suggest that Leksell Gamma Knife
Perfexion will support increased patient volumes while at the same time
improving efficiency and saving physician time."
Mr. Puusepp noted that the
first patients were successfully treated with Leksell Gamma Knife Perfexion
in July at Hôspital la Timone (Timone University Hospital) in Marseille,
France. In a report on the first 30 patients presented at the Congress of
Neurological Surgeons (CNS) annual meeting in Chicago this past October, the
team in Marseille said, "In this preliminary experience Leksell Gamma Knife
Perfexion is turning out to represent a great improvement other
radiosurgical technologies and even over earlier Gamma Knife systems. Our
overall feeling is that this new generation platform for radiosurgery is a
real quantum leap for radiosurgery technology and appears to makes
radiosurgery even easier, faster and safer than before."
About Leksell Gamma
Knife® Perfexion™
Leksell Gamma Knife
Perfexion maintains full clinical compatibility with the classic Leksell
Gamma Knife and is supported by efficacy and outcome data from 400,000
treated patients worldwide and thousands of peer-reviewed scientific
articles, making it a proven choice for radiosurgery of the brain.
According to Elekta, Leksell Gamma Knife Perfexion reduces unwanted body
dose to the patient by up to 100 times compared with competing technologies,
which is particularly important for treatment of children and women of
childbearing age, and allows for a dramatically increased treatable volume,
which is estimated to increase the number of patients that can benefit from
Gamma Knife surgery by up to 40 percent. Elekta estimates that the fully
automated and efficient single push-button approach can save 3-5 working
weeks of physician time per year at an average Gamma Knife center.
About Elekta
Elekta is an international
medical-technology group providing meaningful clinical solutions,
comprehensive information systems and services for improved cancer care and
management of brain disorders. All of Elekta’s solutions employ non-invasive
or minimally invasive techniques and are therefore clinically effective,
gentle on the patient and cost-effective.
Clinical solutions include
among others Leksell Gamma Knife® for non-invasive treatment of
brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in
April 2005, the Elekta Group is the world’s largest supplier of oncology
software.
Elekta’s systems and
solutions are used at over 4,000 hospitals around the world to treat cancer
and manage clinical operations as well as to diagnose and treat brain
disorders, including tumors, vascular malformations and functional
disorders.
With approximately 2,000
employees, Elekta's corporate headquarter is located in Stockholm, Sweden.
For more information about Elekta, please visit
www.elekta.com.
About AMS
American Shared Hospital Services provides turnkey technology solutions for
advanced radiosurgical and radiation therapy services. AMS is the world
leader in providing Gamma Knife radiosurgery services, a non-invasive
treatment for malignant and benign brain tumors, vascular malformations and
trigeminal neuralgia (facial pain). The Company also offers the latest IGRT
and IMRT systems, as well as its proprietary Operating Room for the 21st
Century (OR21®) concept. Through its equity investment in Still River
Systems, AMS also plans to complement these services with the Clinatron-250™
proton beam radiation therapy (PBRT) system, which has not yet been approved
by the FDA. For more information about AMS, please visit
www.ashs.com.
Safe Harbor Statement
This press release may be deemed to contain
certain forward-looking statements with respect to the financial condition,
results of operations and future plans of American Shared Hospital Services,
which involve risks and uncertainties including, but not limited to, the
risks of the Gamma Knife business, the risks of developing its IMRT and The
Operating Room for the 21st Century® programs, and the risks of
investing in a development-stage company, Still River Systems, Inc., without
a proven product. Further information on potential factors that could
affect the financial condition, results of operations and future plans of
American Shared Hospital Services is included in the filings of the Company
with the Securities and Exchange Commission, including the Company's Annual
Report on Form 10-K for the year ended December 31, 2005, the Form 10-Q for
the three months ended March 31, 2006 and June 30, 2006, and the definitive
Proxy Statement for the Annual Meeting of Shareholders on June 28, 2006.
|